Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) stock jumped 0.11% on Monday to $0.18 against a previous-day closing price of $0.18. With 1.54 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.97 million shares. The 52-week range on BCLI shows that it touched its highest point at $3.46 and its lowest point at $0.13 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at -0.17.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BCLI was down-trending over the past week, with a drop of -2.59%, but this was up by 1.24% over a month. Three-month performance dropped to -87.99% while six-month performance fell -93.68%. The stock lost -89.27% in the past year, while it has lost -89.01% so far this year. A look at the trailing 12-month EPS for BCLI yields -0.44 with Next year EPS estimates of -0.46. For the next quarter, that number is -0.11. This implies an EPS growth rate of 18.18% for this year and 14.81% for next year.
Float and Shares Shorts:
At present, 48.98 million BCLI shares are outstanding with a float of 39.59 million shares on hand for trading. On Oct 30, 2023, short shares totaled 3.57 million, which was 7.93% higher than short shares on Sep 28, 2023. In addition to Mr. Chaim Lebovits as the firm’s President & CEO, Dr. Stacy R. Lindborg Ph.D. serves as its Co-Chief Executive Officer.
Institutional Ownership:
Through their ownership of 13.43% of BCLI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.67% of BCLI, in contrast to 4.13% held by mutual funds. Shares owned by individuals account for 12.55%. As the largest shareholder in BCLI with 3.13% of the stake, The Vanguard Group, Inc. holds 1,408,450 shares worth 1,408,450. A second-largest stockholder of BCLI, BlackRock Fund Advisors, holds 461,083 shares, controlling over 1.02% of the firm’s shares. Liberty Wealth Management LLC is the third largest shareholder in BCLI, holding 352,619 shares or 0.78% stake. With a 2.11% stake in BCLI, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 951,371 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.89% of BCLI stock, is the second-largest Mutual Fund holder. It holds 401,014 shares valued at 61355.0. Fidelity Extended Market Index Fu holds 0.41% of the stake in BCLI, owning 183,804 shares worth 28122.0.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BCLI since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BCLI analysts setting a high price target of $10.00 and a low target of $10.00, the average target price over the next 12 months is $10.00. Based on these targets, BCLI could surge 5455.56% to reach the target high and rise by 5455.56% to reach the target low. Reaching the average price target will result in a growth of 5455.56% from current levels.
Summary of Insider Activity:
Insiders traded BCLI stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 11,500 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 309,684 while 0 shares were sold.
